Seal U S, Doe R P, Byar D P, Corle D K
Cancer. 1976 Sep;38(3):1095-107. doi: 10.1002/1097-0142(197609)38:3<1095::aid-cncr2820380309>3.0.co;2-z.
Cholesterol and triglycerides were measured in plasma samples from patient with cancer of the prostate before and after 3 months treatment with either Premarin, Provera, Provera and diethylstilbestrol, or diethylstilbestrol alone. Cholesterol was also measured before and after one of three doses of diethylstilbestrol or placebo. Pretreatment cholesterol levels at 196 +/- 1.3 mg per 100 ml (X +/- SE, N = 1093) were significantly lower than these reported for similar age group noncancer controls. Significant increases occurred with some of the estrogen treatments. Pretreatment cholesterol levels showed a significant negative correlation with age in Stage III and IV patients of both studies and a positive correlation with hemoglobin in Stage III patients of both studies. Pretreatment triglyceride levels at 120 +/- 1.9 mg per 100 ml (X +/- SE, N = 1089) were similar to levels reported for noncancer controls of similar age. Estrogen treatment produced a significant increase in triglyceride levels. Serum triglycerides were significantly correlated with hemoglobin, weight, and cholesterol and negatively correlated with age, Analysis of covariance for both cholesterol and triglycerides showed highly significant treatment effects, but no stage effects and no stage-treatment interactions. It showed that the pretreatment value is of extreme importance for predicting or explaining the 3-month value. Death rates were calculated by level of pretreatment cholesterol or pretreatment triglycerides for all Stage II and IV patients, all treatments combined, and for Study 2 and Study 3 separately. No consistent trends were evident for cholesterol. Spearman correlation coefficients between category of initial triglyceride value and rank of death rate were computed to test for a quadratic effect. When the absolute values of the initial triglyceride values minus the overall mean were correlated with the death rate, a significant negative correlation was found for all causes of death and for deaths due to cardiovascular disease and prostatic cancer. These results indicate that the death rate is highest near the overal mean for initial triglyceride values and decreases as the initial values deviate above or below the mean. Initial triglyceride levels appear to have potential as indicators of risk of death in patients with prostatic cancer. The percentage of patients dead at 1 year by initial triglyceride levels, measured only in Study 3, revealed a pattern similar to that observed for the death rate, that is, the highest percentages were associated with values near the overall mean.
对前列腺癌患者在接受以下治疗3个月前后的血浆样本进行胆固醇和甘油三酯检测：单用倍美力、单用安宫黄体酮、安宫黄体酮与己烯雌酚联用或单用己烯雌酚。还对三种剂量的己烯雌酚或安慰剂之一治疗前后的胆固醇进行了检测。治疗前胆固醇水平为每100毫升196±1.3毫克（X±SE，N = 1093），显著低于相似年龄组非癌症对照者的报告水平。某些雌激素治疗后胆固醇水平显著升高。在两项研究的III期和IV期患者中，治疗前胆固醇水平与年龄呈显著负相关，在两项研究的III期患者中，与血红蛋白呈正相关。治疗前甘油三酯水平为每100毫升120±1.9毫克（X±SE，N = 1089），与相似年龄非癌症对照者报告的水平相似。雌激素治疗使甘油三酯水平显著升高。血清甘油三酯与血红蛋白、体重和胆固醇显著相关，与年龄呈负相关。胆固醇和甘油三酯的协方差分析显示治疗效果高度显著，但无分期效应和分期-治疗交互作用。结果表明，治疗前的值对于预测或解释3个月时的值极为重要。计算了所有II期和IV期患者、所有联合治疗以及分别针对研究2和研究3，按治疗前胆固醇或治疗前甘油三酯水平划分的死亡率。胆固醇方面没有明显一致的趋势。计算初始甘油三酯值类别与死亡率排名之间的斯皮尔曼相关系数以检验二次效应。当初始甘油三酯值减去总体均值的绝对值与死亡率相关时，发现所有死因以及心血管疾病和前列腺癌导致的死亡均存在显著负相关。这些结果表明，初始甘油三酯值接近总体均值时死亡率最高，随着初始值偏离均值上下，死亡率降低。初始甘油三酯水平似乎有潜力作为前列腺癌患者死亡风险的指标。仅在研究3中按初始甘油三酯水平计算的1年时死亡患者百分比显示出与死亡率观察到的模式相似，即最高百分比与接近总体均值的值相关。
